Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1205704 | 0.88 | USP2 (0.45) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL6229260 | 0.83 | ALDH1A1 (0.48) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL576285 | 0.82 | ALDH1A1 (0.39) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL16265090 | 0.80 | — | — | |
| SCHEMBL7481663 | 0.80 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL5873338 | 0.78 | USP2 (0.45) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL4662102 | 0.78 | ALDH1A1 (0.43) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL25203219 | 0.74 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL15125809 | 0.74 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL13636610 | 0.74 | ALDH1A1 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969712-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-6107300-A | CORTICOTROPIN RELEASING FACTOR ANTAGONIST; PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS (US) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | USP2 4219/4885TSHR 239/4885ALDH1A1 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.